Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
A phase 2 trial of Cemiplimab in melanoma and head and neck squamous cell carcinoma, run by Vyriad, Inc., active and no longer recruiting.
Overview
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients is a phase 2 interventional study registered as NCT04291105 by Vyriad, Inc., with 87 participants planned, started 2020-04-24 and due to reach its primary completion in 2026-10. Interventions recorded: VV1, Cemiplimab. Conditions listed: Melanoma, Head and Neck Squamous Cell Carcinoma, Colo-rectal Cancer. No results are recorded here; the registry entry is the source.
Setting
Phase 2 Trial of Voyager VI (Vesicular Stomatitis Virus Expressing NIS and Human Interferon Beta, VV1), in Combination With Cemiplimab in Patients With Select Solid Tumors
Phase
Phase 2
Sponsor
Vyriad, Inc.
Registry
Enrolled
87
Similar pages
not linked directly; found by shared links- TrialA First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Hav
Shares Cemiplimab, Melanoma.
- TrialA Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous
- TrialA Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
Shares Cemiplimab, Melanoma.
- TrialA Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back Af
Shares Cemiplimab, Melanoma.
- TrialAn Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors
- TrialA Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
Shares Cemiplimab, Melanoma.
- TrialNeoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients
- TrialA Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Shares Cemiplimab, Melanoma.